Hamps Bio Limited
Incorporated in 2007, Hamps Bio Ltd is in the business of Pharmaceutical Formulation and Freeze-Drying Ingredient Manufacturing and Distribution[1]
- Market Cap ₹ 22.5 Cr.
- Current Price ₹ 25.8
- High / Low ₹ 35.0 / 13.4
- Stock P/E
- Book Value ₹ 9.39
- Dividend Yield 0.00 %
- ROCE -2.81 %
- ROE -7.66 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 80.1 days to 60.8 days
Cons
- Stock is trading at 2.75 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of 0.89% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 5.34 | 5.58 | 6.48 | 6.67 | 8.52 | |
| 4.72 | 4.71 | 5.31 | 5.90 | 8.41 | |
| Operating Profit | 0.62 | 0.87 | 1.17 | 0.77 | 0.11 |
| OPM % | 11.61% | 15.59% | 18.06% | 11.54% | 1.29% |
| 0.00 | 0.01 | 0.03 | 0.15 | 0.33 | |
| Interest | 0.19 | 0.18 | 0.15 | 0.14 | 0.25 |
| Depreciation | 0.33 | 0.34 | 0.40 | 0.38 | 0.81 |
| Profit before tax | 0.10 | 0.36 | 0.65 | 0.40 | -0.62 |
| Tax % | -20.00% | 0.00% | 23.08% | 25.00% | 6.45% |
| 0.12 | 0.36 | 0.50 | 0.30 | -0.65 | |
| EPS in Rs | 0.40 | 1.20 | 1.28 | 0.34 | -0.75 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 15% |
| TTM: | 28% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -317% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 20% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | 1% |
| Last Year: | -8% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 1.50 | 1.50 | 1.96 | 4.36 | 8.71 |
| Reserves | -0.49 | -0.14 | 1.38 | 4.44 | -0.53 |
| 2.04 | 1.74 | 1.05 | 2.97 | 6.40 | |
| 0.60 | 0.86 | 0.73 | 0.97 | 0.64 | |
| Total Liabilities | 3.65 | 3.96 | 5.12 | 12.74 | 15.22 |
| 2.15 | 2.61 | 2.52 | 2.43 | 7.19 | |
| CWIP | 0.00 | 0.00 | 0.00 | 3.38 | 1.08 |
| Investments | 0.04 | 0.00 | 0.00 | 0.00 | 2.04 |
| 1.46 | 1.35 | 2.60 | 6.93 | 4.91 | |
| Total Assets | 3.65 | 3.96 | 5.12 | 12.74 | 15.22 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 0.33 | 1.23 | -0.29 | -1.77 | -0.43 | |
| 0.51 | -0.75 | -0.37 | -6.20 | -2.86 | |
| -0.94 | -0.48 | 0.67 | 8.00 | 3.23 | |
| Net Cash Flow | -0.10 | 0.00 | 0.01 | 0.04 | -0.06 |
| Free Cash Flow | 0.87 | 0.44 | -0.65 | -5.49 | -3.65 |
| CFO/OP | 53% | 141% | -12% | -216% | -391% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 47.16 | 49.71 | 55.76 | 65.12 | 51.84 |
| Inventory Days | 94.57 | 75.03 | 264.09 | 452.45 | 281.84 |
| Days Payable | 63.05 | 103.42 | 60.12 | 114.06 | 39.27 |
| Cash Conversion Cycle | 78.69 | 21.32 | 259.73 | 403.51 | 294.40 |
| Working Capital Days | -34.86 | -58.22 | 55.20 | 124.22 | 60.83 |
| ROCE % | 17.56% | 21.36% | 6.68% | -2.81% |
Insights
In beta| Mar 2024 | Mar 2025 | |
|---|---|---|
| Number of Manufacturing Units Number |
|
|
| Number of SKUs - FMCG Division (Brand: FRYZEY) Number |
||
| Number of SKUs - Pharma Division Number |
||
| Solar Power Plant Capacity (Ankleshwar Unit) kVA |
||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Management
29 May - M/s Naviwala & Associates appointed internal auditor for FY 2026-27, effective May 29, 2026.
- Results - Financial Results For The Year Ended 31-03-2026 29 May
-
Board Meeting Outcome for Board Meeting Outcome For Approval Of Standalone And Consolidated Audited Financial Results For The Half Year And Year To Date Ended March 31, 2026, Along With Auditor''s Report Thereon Is Attached Herewith.
29 May - Board approved audited standalone and consolidated results for FY2026; appointed Naviwala & Associates as internal auditor.
-
Board Meeting Intimation for Board Meeting Intimation For Approval Of The Audited Standalone And Consolidated Financial Results Of The Company For The Half Year And Year To Date Ended March 31, 2026
25 May - Board meeting on May 29, 2026 to approve audited FY26 results and appoint internal auditor.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
14 Apr - Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 for the quarter ended on March 31, 2026.
Business Overview:[1]
HBL is in the business of ethical marketing and distribution of pharmaceutical formulations across wide range of dosage including tablets, syrups, capsules, injectables, oil, gel and powder used as medicine & nutrition supplements as well as the manufacturing of freeze dried and frozen products such as fruits, vegetables, herbs and flowers.